Jiangsu Vcare Secures Nearly CNY 200 Million in Series C+ Financing
Published Time:
2025-01-22 17:49
Source:
Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) closed its Series C+ financing round, raising nearly CNY 200 million. The round was jointly invested by Xinghe Venture Capital, Jinlong Investment, SDIC Capital, and Yangtze River Industry Group. The proceeds will accelerate clinical advancement of Jiangsu Vcare’s innovative drug pipelines, strengthen its integrated CRO/CDMO service ecosystem, enhance independent innovation capabilities, and advance strategic initiatives in synthetic biology and green chemistry. This brings Jiangsu Vcare’s total equity financing to over CNY 1 billion, demonstrating sustained capital market confidence.
Dr. Gong Yanchun, Co-founder and CEO, stated: "Jiangsu Vcare has always adhered to the strategic layout of dual-wheel drive and coordinated development of its two core businesses: independent research and development of innovative drugs, and full-industry-chain CRO/CDMO services for pharmaceuticals.Three self-developed drug candidates have now entered confirmatory clinical studies, while our CRO/CDMO business continues rapid expansion with increasingly diversified service models. Our forward-looking strategic planning positions us to further solidify core competitiveness. With strong support from investors , we will break new ground, navigate market cycles, and achieve sustainable high-quality development."
Previous Page
Related News
15
2017
/
09
Jiangsu Vcare’s New R&D Center and Headquarter are being constructed
Jiangsu Vcare Pharmaceutical Technology Co., Ltd. bought a 20 mu of land in Biomedical Valley, Nanjing High-tech Industrial Development Zone, Jiangbei New District on August 15, 2017. The area is equipped with metro line 3 and the subway S8. It is about 4 kilometers away from the Nanjing High-speed Railway North Station which is under construction. The surrounding environment is very beautiful and the traffic is very convenient. It is constructed as Vcare’s headquarter and drug research and development center and the center was put into use at the end of 2019.
31
2017
/
08
Jiangsu Vcare Held “Team Building Training” Activity
Jiangsu Vcare held “Team Building Training” activity in the town of Chaxi at the end of August. The activity was divided into several parts and each task is completed within specified time. Participants need to communicate and coordinate with team awareness.
31
2017
/
08
Jiangsu Vcare Held Ten Kilometers Run Activity
87 participants arrived at the main entrance of Xuanwu Lake to participate in a ten-kilometer running activity after warm-up at 7 o'clock on August 31. Six colleagues on a business trip in Hainan and seven colleagues on a business trip in Xi'an also actively participated in the running at the local. Everyone completed the ten-kilometer running after one hour and a half and was very happy to give a test to our physical fitness through the running.
23
2017
/
08
Jiangsu Vcare Was Honored as Jiangbei New Area Lingque Enterprise
In 2017, the list of “Lingque” enterprises in Jiangbei New District of Nanjing was announced and Jiangsu Vcare Pharmaceutical Technology Co., Ltd. was successfully selected into the list. “Lingque” enterprises project aim to select a group of innovative SMEs with high growth in Jiangbei district and provide the selected enterprises with one-stop support such as equity investment, emergency turnover, loan interest subsidy, R&D subsidies, and etc.. To be successfully selected into the “Lingque” enterprises program is an inspiration to the company. Vcare keep integrating various resources to quickly become bigger and stronger to contribute to the development of Jiangbei New Area.
15
2017
/
06
Jiangsu Vcare and Yangzhou Princechem Acquired Boya Chemical Company
The signing ceremony of Jiangsu Vcare Pharmaceutical Technology Co., Ltd. and Yangzhou Princechem Co., Ltd. acquiring Boya Chemical (Nantong) Co., Ltd. was held in the conference room of Jiangsu Vcare recently. Boya Chemical (Nantong) Co., Ltd. is located in Yangkou Chemical Industrial Park, Rudong Coastal Economic Development Zone, Jiangsu Province. The company covers an area of 70 acres and is a Hong Kong-owned enterprise. The goal of this acquisition is to build Boya Chemical into a raw material drug manufacturer that meets the standards of China, the United States and the European Union. After renovation, Boya Chemical will be a chemical raw materials production base of Yatai Group and solve the bottleneck problem of Vcare's raw material drug R&D and production. It’s believed that the acquisition will make a significant contribution to Vcare’s production and sales of intermediates and APIs.
06
2017
/
06
Leaders of Management Committee of Rudong Coastal Economic Development Zone Visited Jiangsu Vcare
Leaders of management committee of Rudong coastal economic development zone visited Jiangsu Vcare on June 1st, 2017. The delegation was received by the vice chairman Jun Qu, general manager Yongqiang Liu, and vice general manager Yanchun Gong of Vcare. The delegation visited the Vcare's chemical research center and drug research center. Mr. Liu introduced R&D progress and advanced equipment to the guests. During the discussion, Mr. Liu introduced the overall development plan of Yatai Group's pharmaceutical industry, and Vcare's development history and the future plan. Mr. Liu also introduced the progress of innovative drug Vicagrel and a series of generic drugs in detail. The leaders of Rudong coastal economic development zone introduced the planning of their park, local investment, environmental protection policies and etc., and expressed their confidence in the research and development prospects of Vcare.